A May 2021 study by the UNC Multidisciplinary IBD Center said,
"The idea with this treatment is to restore the normal function of the protective bacteria in the gut, targeting the source of IBD, instead of treating its symptoms with traditional immunosuppressants that can cause side effects like infections or tumors,"
"It also decreased pathobionts - bacteria that can cause harm - while expanding resident protective bacteria, and produced metabolites promoting mucosal healing and immunoregulatory responses,”
"Simply put - the treatment increased the good guys and decreased the bad guys."